{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:52:33Z","timestamp":1791409953374,"version":"4.3.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s12325-025-03208-5","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T06:19:08Z","timestamp":1747376348000},"page":"3576-3589","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Long-Term Transfusion Independence with Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Lower-Risk Myelodysplastic Syndromes in the COMMANDS Trial"],"prefix":"10.1007","volume":"42","clinical-trial-number":[{"clinical-trial-number":"nct03682536","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3631-2482","authenticated-orcid":false,"given":"Guillermo","family":"Garcia-Manero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer M.","family":"Zeidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami S.","family":"Komrokji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Pozharskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelonitda","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Keeperman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinzhi","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Kalsekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barkha","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimana","family":"Miteva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Valc\u00e1rcel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Fenaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jake","family":"Shortt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo Giovanni","family":"Della Porta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Platzbecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"key":"3208_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/ejh.13619","volume":"107","author":"M Braga Lemos","year":"2021","unstructured":"Braga Lemos M, Rodrigues SR, Schroeder T, Kulasekararaj AG, Matos JE, Tang D. Association between red blood cell transfusion dependence and burden in patients with myelodysplastic syndromes: a systematic literature review and meta-analysis. Eur J Haematol. 2021;107:3\u201323.","journal-title":"Eur J Haematol"},{"key":"3208_CR2","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1002\/ajh.24704","volume":"92","author":"DK Hiwase","year":"2017","unstructured":"Hiwase DK, Singhal D, Strupp C, et al. Dynamic assessment of RBC-transfusion dependency improves the prognostic value of the revised-IPSS in MDS patients. Am J Hematol. 2017;92:508\u201314.","journal-title":"Am J Hematol"},{"key":"3208_CR3","doi-asserted-by":"publisher","first-page":"7567","DOI":"10.1002\/cam4.2638","volume":"8","author":"E Balleari","year":"2019","unstructured":"Balleari E, Filiberti RA, Salvetti C, et al. Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: a propensity score-matched analysis. Cancer Med. 2019;8:7567\u201376.","journal-title":"Cancer Med"},{"key":"3208_CR4","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1182\/blood-2013-07-512442","volume":"122","author":"V Santini","year":"2013","unstructured":"Santini V, Schemenau J, Levis A, et al. Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS? Blood. 2013;122:2286\u20138.","journal-title":"Blood"},{"key":"3208_CR5","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1200\/JCO.2016.71.3271","volume":"35","author":"S Park","year":"2017","unstructured":"Park S, Hamel JF, Toma A, et al. Outcome of lower-risk patients with myelodysplastic syndromes without 5q deletion after failure of erythropoiesis-stimulating agents. J Clin Oncol. 2017;35:1591\u20137.","journal-title":"J Clin Oncol"},{"key":"3208_CR6","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/bjh.15707","volume":"184","author":"S Park","year":"2019","unstructured":"Park S, Greenberg P, Yucel A, et al. Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review. Br J Haematol. 2019;184:134\u201360.","journal-title":"Br J Haematol"},{"key":"3208_CR7","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1038\/s41375-018-0118-9","volume":"32","author":"P Fenaux","year":"2018","unstructured":"Fenaux P, Santini V, Spiriti MAA, et al. A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-alpha in anemic patients with low-risk MDS. Leukemia. 2018;32:2648\u201358.","journal-title":"Leukemia"},{"key":"3208_CR8","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1038\/leu.2017.192","volume":"31","author":"U Platzbecker","year":"2017","unstructured":"Platzbecker U, Symeonidis A, Oliva EN, et al. A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes. Leukemia. 2017;31:1944\u201350.","journal-title":"Leukemia"},{"key":"3208_CR9","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1111\/bjh.16206","volume":"189","author":"P Fenaux","year":"2020","unstructured":"Fenaux P, Platzbecker U, Ades L. How we manage adults with myelodysplastic syndrome. Br J Haematol. 2020;189:1016\u201327.","journal-title":"Br J Haematol"},{"key":"3208_CR10","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000314","volume":"3","author":"U Germing","year":"2019","unstructured":"Germing U, Oliva EN, Hiwase D, Almeida A. Treatment of anemia in transfusion-dependent and non-transfusion-dependent lower-risk MDS: current and emerging strategies. Hemasphere. 2019;3: e314.","journal-title":"Hemasphere"},{"key":"3208_CR11","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/nm.3512","volume":"20","author":"RN Suragani","year":"2014","unstructured":"Suragani RN, Cadena SM, Cawley SM, et al. Transforming growth factor-beta superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat Med. 2014;20:408\u201314.","journal-title":"Nat Med"},{"key":"3208_CR12","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1002\/ajh.23732","volume":"89","author":"KM Attie","year":"2014","unstructured":"Attie KM, Allison MJ, McClure T, et al. A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers. Am J Hematol. 2014;89:766\u201370.","journal-title":"Am J Hematol"},{"key":"3208_CR13","unstructured":"Hayati S, Platzbecker U, Aluri S, et al. Luspatercept improves hematopoiesis in lower-risk myelodysplastic syndromes (MDS): comparative biomarker analysis of ring sideroblast-positive and -negative subgroups from the phase 3 COMMANDS study. Hemasphere. 2024;8."},{"key":"3208_CR14","doi-asserted-by":"crossref","unstructured":"Hayati S, Zeidan AM, Garcia-Manero G, et al. Luspatercept modulates inflammation in the bone marrow, restores effective erythropoiesis\/hematopoiesis, and provides sustained clinical benefit versus epoetin alfa (EA): biomarker analysis from the phase 3 COMMANDS study. Blood. 2023;142:Abstract 1845.","DOI":"10.1182\/blood-2023-178674"},{"key":"3208_CR15","volume-title":"Reblozyl\u00ae (luspatercept) [prescribing information]","author":"Bristol Myers Squibb","year":"2024","unstructured":"Bristol Myers Squibb. Reblozyl\u00ae (luspatercept) [prescribing information]. Summit: Celgene Corporation; 2024."},{"key":"3208_CR16","doi-asserted-by":"publisher","first-page":"e646","DOI":"10.1016\/S2352-3026(24)00203-5","volume":"11","author":"MG Della Porta","year":"2024","unstructured":"Della Porta MG, Garcia-Manero G, Santini V, et al. Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial. Lancet Haematol. 2024;11:e646\u201358.","journal-title":"Lancet Haematol"},{"key":"3208_CR17","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S0140-6736(23)00874-7","volume":"402","author":"U Platzbecker","year":"2023","unstructured":"Platzbecker U, Della Porta MG, Santini V, et al. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial. Lancet. 2023;402:373\u201385.","journal-title":"Lancet"},{"key":"3208_CR18","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","volume":"108","author":"BD Cheson","year":"2006","unstructured":"Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419\u201325.","journal-title":"Blood"},{"key":"3208_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.38","volume":"8","author":"S Mukherjee","year":"2024","unstructured":"Mukherjee S, Brown-Bickerstaff C, Falkenstein A, et al. Treatment patterns and outcomes with luspatercept in patients with lower-risk myelodysplastic syndromes: a retrospective US cohort analysis. Hemasphere. 2024;8:e38.","journal-title":"Hemasphere"},{"key":"3208_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2024.107624","volume":"148","author":"LA Andritsos","year":"2025","unstructured":"Andritsos LA, McBride A, Tang D, et al. Real-world impact of luspatercept on red blood cell transfusions among patients with myelodysplastic syndromes: a United States healthcare claims database study. Leuk Res. 2025;148:107624.","journal-title":"Leuk Res"},{"key":"3208_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70086","volume":"9","author":"A Consagra","year":"2025","unstructured":"Consagra A, Lanino L, Al Ali NH, et al. Response to luspatercept can be predicted and improves overall survival in the real-life treatment of LR-MDS. Hemasphere. 2025;9:e70086.","journal-title":"Hemasphere"},{"key":"3208_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13092702","volume":"13","author":"R Boccia","year":"2024","unstructured":"Boccia R, Xiao H, von Wilamowitz-Moellendorff C, et al. A systematic literature review of predictors of erythropoiesis-stimulating agent failure in lower-risk myelodysplastic syndromes. J Clin Med. 2024;13:2702.","journal-title":"J Clin Med"},{"key":"3208_CR23","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1182\/blood.2020004850","volume":"136","author":"L Malcovati","year":"2020","unstructured":"Malcovati L, Stevenson K, Papaemmanuil E, et al. SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood. 2020;136:157\u201370.","journal-title":"Blood"},{"key":"3208_CR24","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/ajh.26090","volume":"96","author":"MM Patnaik","year":"2021","unstructured":"Patnaik MM, Tefferi A. Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS\/myeloproliferative neoplasm with RS and thrombocytosis (MDS\/MPN-RS-T)\u2014\u201c2021 update on diagnosis, risk-stratification, and management.\u201d Am J Hematol. 2021;96:379\u201394.","journal-title":"Am J Hematol"},{"key":"3208_CR25","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1080\/10428194.2020.1719088","volume":"61","author":"V Santini","year":"2020","unstructured":"Santini V, Almeida A, Giagounidis A, et al. Achievement of red blood cell transfusion independence in red blood cell transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes correlates with serum erythropoietin levels. Leuk Lymphoma. 2020;61:1475\u201383.","journal-title":"Leuk Lymphoma"},{"key":"3208_CR26","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJMoa1908892","volume":"382","author":"P Fenaux","year":"2020","unstructured":"Fenaux P, Platzbecker U, Mufti GJ, et al. Luspatercept in patients with lower-risk myelodysplastics syndromes. N Engl J Med. 2020;382:140\u201351.","journal-title":"N Engl J Med"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03208-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03208-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03208-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T08:14:08Z","timestamp":1750493648000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03208-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["3208"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03208-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]},"assertion":[{"value":"7 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Valeria Santini has been a member of the board of directors or an advisory board for AbbVie, Bristol Myers Squibb\/Celgene, CTI, Geron, Jazz, Keros, Novartis, Servier, and Syros. Amer M. Zeidan has consulted for AbbVie, Agios, Akeso Pharma, ALX Oncology, Amgen, Astellas, BeiGene, BioCryst, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Chiesi, Daiichi Sankyo, Epizyme, Faron, Genentech, Geron, Gilead, GlycoMimetics, Hikma, Janssen, Karyopharm, Kura Oncology, Kyowa Kirin, LAVA Therapeutics, Mendus, Notable Labs, Novartis, Orum, Otsuka, Pfizer, Regeneron, Rigel, Schr\u00f6dinger, Servier, Sumitomo, Syndax, Syros, Taiho, Takeda, Treadwell, Vincerx, and Zentalis; has received research funding from AbbVie, Amgen, Astex, Bristol Myers Squibb, Celgene, Geron, Kura, Novartis, Otsuka, Shattuck Labs, Syros, and Takeda; and has received honoraria from AbbVie, Agios, Akeso Pharma, ALX Oncology, Amgen, Astellas, BeiGene, BioCryst, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Chiesi, Daiichi Sankyo, Epizyme, Faron, Genentech, Geron, Gilead, GlycoMimetics, Hikma, Janssen, Karyopharm, Kura Oncology, Kyowa Kirin, LAVA Therapeutics, Mendus, Notable Labs, Novartis, Orum, Otsuka, Pfizer, Regeneron, Rigel, Schr\u00f6dinger, Servier, Sumitomo, Syndax, Syros, Taiho, Takeda, Treadwell, Vincerx, and Zentalis. Rami S. Komrokji has participated in advisory boards for Bristol Myers Squibb, Daiichi Sankyo, Jazz, PharmaEssentia, Rigel, Servier, Sobi, and Sumitomo; has received research grants from Bristol Myers Squibb; has consulted for Geron and Genentech; and has participated in speakers\u2019 bureaux for PharmaEssentia, Rigel, Servier, and Sobi. Veronika Pozharskaya is an employee of Bristol Myers Squibb and holds stock in Bristol Myers Squibb and Merck. Shelonitda Rose has received travel support from Bristol Myers Squibb and holds stock in Bristol Myers Squibb\/Celgene. Yinzhi Lai, Sameer Kalsekar, Barkha Aggarwal, and Karen Keeperman are employees of and hold stock in Bristol Myers Squibb. Dimana Miteva is an employee of Bristol Myers Squibb. David Valc\u00e1rcel has consulted for Amgen, Astellas, Bristol Myers Squibb\/Celgene, Janssen, Jazz, Merck Sharpe & Dohme, Novartis, Pfizer, Sanofi, Sobi, and Takeda; has received honoraria from Amgen, Astellas, Bristol Myers Squibb\/Celgene, Janssen, Jazz, Merck Sharpe & Dohme, Novartis, Pfizer, Sanofi, Sobi, and Takeda; and has received meeting and travel support from AbbVie, Bristol Myers Squibb\/Celgene, Jazz, Novartis, and Sobi. Pierre Fenaux has received research funding (as the GFM chairperson) from AbbVie, Astex, Bristol Myers Squibb, Novartis, and Servier; and has received honoraria from AbbVie and Bristol Myers Squibb. Jake Shortt has received research funding from Astex\/Taiho; has consulted for Astellas, Bristol Myers Squibb, Novartis, Otsuka, and Pfizer; has received honoraria from Novartis and Mundipharma; and has participated on the ELEMENT trial steering committee for Bristol Myers Squibb (paid to institution). Matteo Giovanni Della Porta has received honoraria from and participated on a data safety monitoring or advisory board for Bristol Myers Squibb. Uwe Platzbecker has received grant support (paid to GWT-TUD) from Amgen and Janssen; has received lecture fees and grant support (paid to the University of Leipzig) from Amgen; has received grant support (paid to the University of Dresden) from Merck and Novartis; has consulted for AbbVie, Bristol Myers Squibb, Curis, Geron, and Novartis; has received honoraria from Bristol Myers Squibb; has received travel support from Bristol Myers Squibb; and is a member of the board of directors or an advisory board for the MDS Foundation. Guillermo Garcia-Manero has nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The trial was performed in accordance with the Declaration of Helsinki and International Counsel on Harmonisation guidelines and received review board approval from each participating site\u2019s institutional review board\/ethics committee. All patients provided written informed consent documentation prior to trial entry.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}